960x0

When It Comes To Healthcare Costs, New Medicines Are The Solution, Not The Problem

There is legitimate concern about healthcare costs, so it is important to understand what matters and what works. Simply put, medical innovation saves lives and over the past decade has reduced health expenditures by more than $1.5 trillion, Forbes writes.

Yet the real measures of this progress are the millions of Americans who are living active lives because of disease-altering treatments, despite their medical conditions. Take Don Wright, who at age 62 was diagnosed with multiple myeloma, an incurable blood cancer, and told he had no more than three years to live.

Thanks to medical innovation, Don is alive 13 years later.

He recently completed his 100th marathon since his diagnosis.

Don Wright is but one example of how new medicines are transforming people’s lives.

Today, more than 30 million diabetes patients are benefiting from new medicines that offer better control of glucose levels. Innovative therapies have helped cut deaths from heart disease in half and reduce by 20% cardiovascular disease’s share of national health expenditures.

Also of note, new cancer therapies are linked to a 25% decrease in disease-related deaths since 1991 and a societal economic benefit of $2 trillion.

All of this tremendous progress has been achieved while retail expenditures on life-enhancing therapies have remained steady at just 10% of total U.S. healthcare spending. In fact, as a percentage of the healthcare dollar, retail prescription medicine costs are the same today as in 1960, and are projected to remain no higher than this level for at least the next 10 years.

That’s remarkable stability–maintaining the same rate of spending when more than 550 new medicines have been approved over the past 15 years.

It is certainly true that many of the newest innovative medicines have a high cost.

However, these “specialty” medicines, such as treatments for cancer, HIV/AIDS and multiple sclerosis, comprise less than 4% of total healthcare expenditures and are taken by less than 1% of all patients.

Yet notwithstanding the immense value of these therapies to patients and society, many insurance plans impose disproportionate cost burdens on patients who need specialty medicines, requiring patients to pay on average five times more out of pocket for medicines than for hospital care.

To change this situation, here is a straightforward principle: treatments that provide the greatest health impact for seriously ill people should have the lowest cost-sharing requirements.

Additionally, the most vulnerable patients must be protected from insurance company practices that delay or deny them needed care, such as adverse tiering and step therapy.

Despite these insurance shortcomings, the good news is that the virtuous cycle of medical innovation continues to deliver.

Today 89% of prescriptions are filled as generics, at prices 75% to 90% lower than the original patented medicines. This incredible value is built into our healthcare system by design.

The cost of innovative medicines plummets after a period of patent protection, providing the best medical solutions in the world at the lowest costs to society for generations, while incentivizing medical researchers to continue developing new and even better therapies.

We are in an unparalleled time of medical advances that can continue to improve patients’ lives, increase life expectancy and reduce the economic burden on healthcare systems. The United States is leading the way, developing 57% of the world’s breakthrough medicines.

But we can maintain this momentum only if patients have access to the medicines they need. What’s the point of developing innovative new medicines if patients cannot benefit from them?

All healthcare stakeholders should work together to promote reforms that enhance broad, affordable access for patients and eliminate cost-sharing hurdles that may discriminate against patients who need care the most.

Share this article: